EA201991203A1 - Способы лечения ожирения антителами к angptl8 - Google Patents
Способы лечения ожирения антителами к angptl8Info
- Publication number
- EA201991203A1 EA201991203A1 EA201991203A EA201991203A EA201991203A1 EA 201991203 A1 EA201991203 A1 EA 201991203A1 EA 201991203 A EA201991203 A EA 201991203A EA 201991203 A EA201991203 A EA 201991203A EA 201991203 A1 EA201991203 A1 EA 201991203A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- angptl8
- methods
- angibility
- obstruction
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423639P | 2016-11-17 | 2016-11-17 | |
| PCT/US2017/062103 WO2018094112A1 (en) | 2016-11-17 | 2017-11-16 | Methods of treating obesity with anti-angptl8 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991203A1 true EA201991203A1 (ru) | 2019-10-31 |
Family
ID=60655071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991203A EA201991203A1 (ru) | 2016-11-17 | 2017-11-16 | Способы лечения ожирения антителами к angptl8 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10442856B2 (https=) |
| EP (1) | EP3541839A1 (https=) |
| JP (1) | JP7133551B2 (https=) |
| KR (1) | KR20190078650A (https=) |
| CN (1) | CN110036029A (https=) |
| AU (1) | AU2017363143B2 (https=) |
| CA (1) | CA3044249A1 (https=) |
| EA (1) | EA201991203A1 (https=) |
| IL (1) | IL266564A (https=) |
| MA (1) | MA46842A (https=) |
| MX (1) | MX382035B (https=) |
| WO (1) | WO2018094112A1 (https=) |
| ZA (1) | ZA201902608B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| AU2018366122A1 (en) | 2017-11-10 | 2020-04-23 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| CN114423787B (zh) | 2019-07-19 | 2025-01-24 | 昂科里斯庞斯公司 | 免疫调节性抗体及其使用方法 |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN111690058B (zh) * | 2020-03-30 | 2021-02-05 | 三优生物医药(上海)有限公司 | 针对冠状病毒的具有中和活性的抗体及其用途 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US20030068623A1 (en) | 1997-06-16 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7393663B2 (en) | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| KR100510795B1 (en) | 1999-08-31 | 2005-08-30 | Compositions and Methods for the Treatment of Tumor | |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
| BRPI0812384A2 (pt) | 2007-05-22 | 2014-12-02 | Novartis Ag | Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 |
| EP2679234A3 (en) | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| RS62769B1 (sr) * | 2016-04-08 | 2022-01-31 | Regeneron Pharma | Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 |
-
2017
- 2017-11-16 EA EA201991203A patent/EA201991203A1/ru unknown
- 2017-11-16 CN CN201780070860.4A patent/CN110036029A/zh active Pending
- 2017-11-16 EP EP17812128.1A patent/EP3541839A1/en active Pending
- 2017-11-16 CA CA3044249A patent/CA3044249A1/en not_active Abandoned
- 2017-11-16 JP JP2019526287A patent/JP7133551B2/ja active Active
- 2017-11-16 WO PCT/US2017/062103 patent/WO2018094112A1/en not_active Ceased
- 2017-11-16 AU AU2017363143A patent/AU2017363143B2/en not_active Expired - Fee Related
- 2017-11-16 KR KR1020197017245A patent/KR20190078650A/ko not_active Ceased
- 2017-11-16 MX MX2019005651A patent/MX382035B/es unknown
- 2017-11-16 MA MA046842A patent/MA46842A/fr unknown
- 2017-11-17 US US15/815,881 patent/US10442856B2/en active Active
-
2019
- 2019-04-24 ZA ZA2019/02608A patent/ZA201902608B/en unknown
- 2019-05-12 IL IL266564A patent/IL266564A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110036029A (zh) | 2019-07-19 |
| AU2017363143A1 (en) | 2019-05-23 |
| MX382035B (es) | 2025-03-13 |
| US10442856B2 (en) | 2019-10-15 |
| AU2017363143B2 (en) | 2022-07-28 |
| JP7133551B2 (ja) | 2022-09-08 |
| ZA201902608B (en) | 2020-07-29 |
| KR20190078650A (ko) | 2019-07-04 |
| US20180134781A1 (en) | 2018-05-17 |
| EP3541839A1 (en) | 2019-09-25 |
| MX2019005651A (es) | 2019-11-12 |
| IL266564A (en) | 2019-07-31 |
| MA46842A (fr) | 2019-09-25 |
| JP2020500852A (ja) | 2020-01-16 |
| CA3044249A1 (en) | 2018-05-24 |
| WO2018094112A1 (en) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991203A1 (ru) | Способы лечения ожирения антителами к angptl8 | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| MX2020009861A (es) | Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos. | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| JOP20190093A1 (ar) | أجسام مضادة لـ il-33 واستخداماتها | |
| EA201690243A1 (ru) | Антитела к активину а и их применение | |
| EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| EA201790530A1 (ru) | Агенты, связывающиеся с cd123, и виды их применения | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| EA201501061A1 (ru) | Антитела к igf-1r с элиминированной способностью связываться с fcrn и их применение для лечения сосудистых глазных заболеваний | |
| MX2015011772A (es) | Anticuerpos anti-hepcidina y usos de los mismos. | |
| EA201492282A1 (ru) | Антагонистические антигенсвязывающие белки к двум рецепторам и их применение | |
| MX2022014995A (es) | Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april. | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
| EA201992460A1 (ru) | Антитела-агонисты btla и их применение | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| EA201891594A1 (ru) | Антитела к il-17c | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека |